• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

分次分子放射治疗中的生物有效剂量——(131)I-间碘苄胍在神经母细胞瘤治疗中的应用

Biologically effective dose in fractionated molecular radiotherapy--application to treatment of neuroblastoma with (131)I-mIBG.

作者信息

Mínguez Pablo, Gustafsson Johan, Flux Glenn, Gleisner Katarina Sjögreen

机构信息

Department of Medical Radiation Physics, Clinical Sciences Lund, Lund University, 22185 Lund, Sweden. Department of Medical Physics, Gurutzeta/Cruces University Hospital, 48903 Barakaldo, Spain.

出版信息

Phys Med Biol. 2016 Mar 21;61(6):2532-51. doi: 10.1088/0031-9155/61/6/2532. Epub 2016 Mar 7.

DOI:10.1088/0031-9155/61/6/2532
PMID:26948833
Abstract

In this work, the biologically effective dose (BED) is investigated for fractionated molecular radiotherapy (MRT). A formula for the Lea-Catcheside G-factor is derived which takes the possibility of combinations of sub-lethal damage due to radiation from different administrations of activity into account. In contrast to the previous formula, the new G-factor has an explicit dependence on the time interval between administrations. The BED of tumour and liver is analysed in MRT of neuroblastoma with (131)I-mIBG, following a common two-administration protocol with a mass-based activity prescription. A BED analysis is also made for modified schedules, when due to local regulations there is a maximum permitted activity for each administration. Modifications include both the simplistic approach of delivering this maximum permitted activity in each of the two administrations, and also the introduction of additional administrations while maintaining the protocol-prescribed total activity. For the cases studied with additional (i.e. more than two) administrations, BED of tumour and liver decreases at most 12% and 29%, respectively. The decrease in BED of the tumour is however modest compared to the two-administration schedule using the maximum permitted activity, where the decrease compared to the original schedule is 47%.

摘要

在这项工作中,对分次分子放射治疗(MRT)的生物有效剂量(BED)进行了研究。推导了Lea-Catcheside G因子的公式,该公式考虑了由于不同给药活度的辐射导致的亚致死损伤组合的可能性。与先前的公式不同,新的G因子明确依赖于给药之间的时间间隔。在采用基于质量的活度处方的常见两次给药方案后,用(131)I-间碘苄胍对神经母细胞瘤进行MRT时,分析了肿瘤和肝脏的BED。当由于当地法规对每次给药有最大允许活度时,还对修改后的方案进行了BED分析。修改包括在两次给药中的每次都给予这种最大允许活度的简单方法,以及在保持方案规定的总活度的同时引入额外的给药。对于研究的有额外(即超过两次)给药的情况,肿瘤和肝脏的BED分别最多降低12%和29%。然而,与使用最大允许活度的两次给药方案相比,肿瘤BED的降低幅度较小,与原始方案相比降低了47%。

相似文献

1
Biologically effective dose in fractionated molecular radiotherapy--application to treatment of neuroblastoma with (131)I-mIBG.分次分子放射治疗中的生物有效剂量——(131)I-间碘苄胍在神经母细胞瘤治疗中的应用
Phys Med Biol. 2016 Mar 21;61(6):2532-51. doi: 10.1088/0031-9155/61/6/2532. Epub 2016 Mar 7.
2
Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma.用于神经母细胞瘤131I-MIBG放射性核素治疗个体化治疗计划的全身剂量测定
J Nucl Med. 2009 Sep;50(9):1518-24. doi: 10.2967/jnumed.109.064469.
3
Targeting of meta-iodobenzylguanidine to SK-N-SH human neuroblastoma xenografts: tissue distribution, metabolism and therapeutic efficacy.间碘苄胍对SK-N-SH人神经母细胞瘤异种移植瘤的靶向作用:组织分布、代谢及治疗效果。
Int J Cancer. 2000 Aug 1;87(3):412-22. doi: 10.1002/1097-0215(20000801)87:3<412::aid-ijc16>3.0.co;2-x.
4
Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma.用于治疗神经母细胞瘤的放射性标记间碘苄胍
Nucl Med Biol. 2008 Aug;35 Suppl 1(Suppl 1):S35-48. doi: 10.1016/j.nucmedbio.2008.05.002.
5
Improved outcome of I-mIBG treatment through combination with external beam radiotherapy in the SK-N-SH mouse model of neuroblastoma.在神经母细胞瘤的SK-N-SH小鼠模型中,通过与外照射放疗联合使用,改善了碘-间位碘代苄胍(I-mIBG)治疗的效果。
Radiother Oncol. 2017 Sep;124(3):488-495. doi: 10.1016/j.radonc.2017.05.002. Epub 2017 Jun 5.
6
Local delivery of (131)I-MIBG to treat peritoneal neuroblastoma.局部注射(131)I - 间碘苄胍治疗腹膜神经母细胞瘤。
Eur J Nucl Med Mol Imaging. 2003 Sep;30(9):1246-50. doi: 10.1007/s00259-003-1214-1. Epub 2003 Jun 17.
7
Targeted radiotherapy of multicell neuroblastoma spheroids with high specific activity [125I]meta-iodobenzylguanidine.用高比活度[125I]间碘苄胍对多细胞神经母细胞瘤球体进行靶向放疗。
Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):425-32. doi: 10.1016/s0360-3016(98)00061-3.
8
Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.无载体添加 131I-间碘苄胍剂量递增研究用于复发性或难治性神经母细胞瘤:神经母细胞瘤治疗新方法联盟试验。
J Nucl Med. 2012 Jul;53(7):1155-63. doi: 10.2967/jnumed.111.098624. Epub 2012 Jun 14.
9
Optimization of molecular radiotherapy with [131I]-meta Iodobenzylguanidine for high-risk neuroblastoma.使用[131I]-间碘苄胍对高危神经母细胞瘤进行分子放射治疗的优化。
Q J Nucl Med Mol Imaging. 2013 Mar;57(1):66-78.
10
Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).全身辐射剂量对神经母细胞瘤患者接受131I-间碘苄胍(MIBG)治疗后反应及毒性的影响
Pediatr Blood Cancer. 2016 Mar;63(3):436-42. doi: 10.1002/pbc.25816. Epub 2015 Oct 27.

引用本文的文献

1
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands.EANM 剂量学委员会关于 177Lu 标记的生长抑素受体和 PSMA 靶向配体剂量学的建议。
Eur J Nucl Med Mol Imaging. 2022 May;49(6):1778-1809. doi: 10.1007/s00259-022-05727-7. Epub 2022 Mar 14.
2
Personalized Dosimetry in Targeted Radiation Therapy: A Look to Methods, Tools and Critical Aspects.靶向放射治疗中的个性化剂量测定:方法、工具及关键方面概述
J Pers Med. 2022 Feb 2;12(2):205. doi: 10.3390/jpm12020205.
3
Personalized dosimetry for a deeper understanding of metastatic response to high activity I-mIBG therapy in high risk relapsed refractory neuroblastoma.
个性化剂量测定,以更深入了解高危复发难治性神经母细胞瘤对高活性I-间碘苄胍治疗的转移反应。
Quant Imaging Med Surg. 2022 Feb;12(2):1299-1310. doi: 10.21037/qims-21-548.
4
EANM position paper on the role of radiobiology in nuclear medicine.EANM 关于放射生物学在核医学中作用的立场文件。
Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3365-3377. doi: 10.1007/s00259-021-05345-9. Epub 2021 Apr 29.
5
EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for I mIBG treatment of neuroendocrine tumours.欧洲核医学协会剂量测定委员会关于碘-间位碘代苄胍(I mIBG)治疗神经内分泌肿瘤内照射剂量测定标准操作程序的系列文章
EJNMMI Phys. 2020 Mar 6;7(1):15. doi: 10.1186/s40658-020-0282-7.
6
Perspectives for Concepts of Individualized Radionuclide Therapy, Molecular Radiotherapy, and Theranostic Approaches.个体化放射性核素治疗、分子放射治疗及诊疗一体化方法的概念展望。
Nucl Med Mol Imaging. 2019 Jun;53(3):167-171. doi: 10.1007/s13139-019-00586-x. Epub 2019 Jan 29.